Apyx Medical（APYX）株式概要
エネルギー技術企業であるエイピックス・メディカル・コーポレーションは、電気外科機器および医療機器の設計、開発、製造、販売を米国内外で行っている。 詳細
APYX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Apyx Medical Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.61 |
| 52週高値 | US$5.08 |
| 52週安値 | US$1.59 |
| ベータ | 1.39 |
| 1ヶ月の変化 | 17.60% |
| 3ヶ月変化 | 27.35% |
| 1年変化 | 161.93% |
| 3年間の変化 | -33.19% |
| 5年間の変化 | -54.18% |
| IPOからの変化 | 40.48% |
最新ニュース
ナラティブの更新 • May 30
APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside
Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple. Analyst Commentary Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.分析記事 • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...Recent updates
ナラティブの更新 • May 30
APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside
Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple. Analyst Commentary Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.分析記事 • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...ナラティブの更新 • May 05
APYX: GLP 1 Skin Tightening And New Tools Will Drive Upside
Analysts have raised their Apyx Medical price target to $6 from $5, citing a stronger recent quarter, higher 2026 guidance and added potential from new product approvals, geographic expansion and growing demand linked to GLP-1 usage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent quarter, where sales were in line and earnings were ahead of expectations, as support for a higher valuation framework.ナラティブの更新 • Apr 21
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.ナラティブの更新 • Apr 05
APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.ナラティブの更新 • Mar 22
APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.ナラティブの更新 • Mar 06
APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).ナラティブの更新 • Feb 19
APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).ナラティブの更新 • Feb 03
APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.分析記事 • Feb 03
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...ナラティブの更新 • Jan 20
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.分析記事 • Jan 13
Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...ナラティブの更新 • Jan 06
APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.ナラティブの更新 • Dec 22
APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.ナラティブの更新 • Dec 08
APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.ナラティブの更新 • Nov 24
APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.分析記事 • Nov 18
Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...分析記事 • Nov 07
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Apyx Medical Corporation ( NASDAQ:APYX ), is not the largest company out there, but it received a lot of attention from...ナラティブの更新 • Nov 07
APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.分析記事 • Oct 04
Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...分析記事 • Sep 19
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 26
A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...分析記事 • Apr 23
The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
To the annoyance of some shareholders, Apyx Medical Corporation ( NASDAQ:APYX ) shares are down a considerable 25% in...
新しいナラティブ • Apr 11
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.分析記事 • Mar 05
Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 0.9x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending very bullish...分析記事 • Dec 19
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
While Apyx Medical Corporation ( NASDAQ:APYX ) might not have the largest market cap around , it led the NASDAQGS...分析記事 • Nov 23
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...分析記事 • Sep 14
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Key Insights The projected fair value for Apyx Medical is US$1.98 based on 2 Stage Free Cash Flow to Equity Apyx...分析記事 • Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Key Insights Apyx Medical will host its Annual General Meeting on 8th of August Salary of US$482.5k is part of CEO...分析記事 • Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Unfortunately for some shareholders, the Apyx Medical Corporation ( NASDAQ:APYX ) share price has dived 25% in the last...分析記事 • Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Market forces rained on the parade of Apyx Medical Corporation ( NASDAQ:APYX ) shareholders today, when the analysts...株主還元
| APYX | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 21.6% | 2.7% | -4.1% |
| 1Y | 161.9% | -20.8% | 20.6% |
業界別リターン: APYX過去 1 年間で-20.8 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: APYX過去 1 年間で20.6 % の収益を上げたUS市場を上回りました。
価格変動
| APYX volatility | |
|---|---|
| APYX Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: APYXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: APYXの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1982 | 205 | Charlie Goodwin | apyxmedical.com |
エネルギー技術企業であるエイピックス・メディカル・コーポレーションは、電気外科機器および医療機器の設計、開発、製造、販売を米国内外で行っている。同社は2つのセグメントで事業を展開している：Surgical AestheticsとOriginal Equipment Manufacturing (OEM)である。同社は、開腹手術や低侵襲手術の際に軟部組織を切開、凝固、切除するためのRFエネルギーとヘリウムプラズマを供給するヘリウムプラズマ発生器や、開腹手術や腹腔鏡手術用の単回使用ハンドピースとアクセサリーのポートフォリオを提供している。同社のヘリウムプラズマ技術製品は、美容外科市場ではRenuvionの名称で、病院外科市場ではJ-Plasmaの名称で販売されている。また、OEMジェネレーターや関連アクセサリーの開発・製造も行っている。同社は以前はBovie Medical Corporationとして知られていたが、2019年1月にAppyx Medical Corporationに社名を変更した。アピックス・メディカル・コーポレーションは1982年に法人化され、フロリダ州クリアウォーターに本社を置いている。
Apyx Medical Corporation 基礎のまとめ
| APYX 基礎統計学 | |
|---|---|
| 時価総額 | US$203.51m |
| 収益（TTM） | -US$9.17m |
| 売上高(TTM) | US$55.90m |
3.5x
P/Sレシオ-21.1x
PER（株価収益率APYX は割高か？
公正価値と評価分析を参照収益と収入
| APYX 損益計算書（TTM） | |
|---|---|
| 収益 | US$55.90m |
| 売上原価 | US$20.60m |
| 売上総利益 | US$35.30m |
| その他の費用 | US$44.47m |
| 収益 | -US$9.17m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.22 |
| グロス・マージン | 63.15% |
| 純利益率 | -16.40% |
| 有利子負債／自己資本比率 | 268.1% |
APYX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/10 12:19 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Apyx Medical Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |